Agios scraps sickle cell drug programme on underwhelming Phase II data

Phase 2negativetebapivatNegative

AI Analysis

Summary

Agios terminated its Phase II sickle cell disease program with tebapivat based on underwhelming data. This termination follows the company's May 2026 discontinuation of tebapivat in myelodysplastic syndrome due to efficacy concerns.

Clinical Trial Data

Phase

Phase II

Primary Endpoint

Not Met

Outcome Details

Phase II data underwhelming, program terminated

Importance:7/10

Sentiment:

-0.90

program terminationsickle cell diseasePhase II failureefficacy concerns

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on July 21, 2026 1:56 PM

Read Original